01 Automated Nucleic Acid Amplification Testing Automated nucleic acid amplification testing is becoming more important as European TB programs seek faster detection of TB and drug resistance with less manual laboratory work. The transition toward low- and moderate-complexity automated NAAT platforms supports decentralized testing and quicker reporting, with WHO reporting pooled sensitivity of 93.0% for TB detection for moderate-complexity automated NAATs. This shift expands the role of automated molecular diagnostics across European laboratories and supports faster treatment decisions.
02 Digital Integration of TB Laboratory Data Digital integration is linking TB laboratory results with surveillance systems to improve data quality, reporting, and disease monitoring across Europe. The transition toward connected laboratory and surveillance platforms supports more consistent sharing of diagnostic information, while ECDC’s 2026 laboratory handbook highlights the need for robust laboratory data to support European surveillance systems. This integration enables health authorities to use diagnostic data more efficiently for europe-tb-diagnostics-market analysis and public-health response.
01 Adoption of Targeted Next-Generation Sequencing for Drug Resistance and Strengthening of Laboratory Quality and Accreditation Drive Market Drug-resistant TB surveillance programs and reference laboratories need detailed resistance profiles to support treatment selection and epidemiological monitoring.Targeted next-generation sequencing can identify multiple resistance-associated mutations from TB samples, increasing demand for sequencing reagents, panels, and specialized laboratory services. European reference laboratories already use genome-sequencing approaches for TB molecular typing and resistance-related work, providing a practical application. Wider use of targeted sequencing can expand the diagnostic supply base beyond conventional resistance-testing methods.TB laboratories and national reference laboratories require standardized procedures and quality systems to maintain reliable diagnostic results across Europe. ISO 15189 accreditation requires validated methods, staff competency, equipment control, internal audits, and continuous quality monitoring, increasing demand for quality-assurance services and diagnostic materials. ECDC's European Reference Laboratory Network for TB supports external quality-assessment programs and harmonization of laboratory methods across EU/EEA countries. Greater laboratory compliance can support demand for validated TB diagnostic systems, proficiency-testing materials, and laboratory quality-management solutions.
01 Budget Constraints in Public Healthcare Systems and Complex Regulatory Requirements for Diagnostic Devices Restrain Market Expansion Budget constraints in public healthcare systems limit spending on advanced TB screening, molecular tests, laboratory equipment, and diagnostic programs.Restricted healthcare budgets can delay procurement and reduce the availability of newer diagnostic technologies across some healthcare facilities.This funding pressure can slow diagnostic capacity expansion and limit adoption of advanced TB diagnostics.Complex regulatory requirements require diagnostic manufacturers to complete extensive validation, documentation, quality, and compliance procedures before market entry.These requirements increase development costs and extend the time needed to introduce new TB diagnostic devices.This regulatory burden can delay technology adoption and reduce the pace of product innovation in the market.
01 AI-Based Chest X-Ray Screening Solutions and Multiplex TB and Respiratory Infection Testing Offers Growth Opportunities Public health programs, hospitals, and radiology providers are key users, as AI can support rapid TB screening and triage from chest X-rays. Diagnostic technology companies can generate revenue through AI software licensing, screening platforms, and integration services. Companies such as Qure.ai, Delft Imaging, and Lunit already offer AI-based TB chest X-ray solutions.Hospitals, diagnostic laboratories, and respiratory-care providers are key users seeking broader testing from a single diagnostic workflow. Diagnostic manufacturers can create new revenue through multiplex assays that detect TB alongside other respiratory pathogens, expanding test menus and laboratory applications. The opportunity supports broader respiratory diagnostics beyond standalone TB testing, creating additional applications for assay developers. .
01 Competition from a Rapidly Expanding Diagnostic Pipeline and Procurement and Equipment Supply Delays Hinders Growth The growing number of emerging TB diagnostic technologies increases competitive and development pressure on existing manufacturers. WHO reported almost 100 TB diagnostic products in development in August 2025, requiring companies to differentiate products through accuracy, speed, workflow, and accessibility. Frequent product innovation can shorten technology cycles and increase the need for continuous product development. Smaller diagnostic companies may find it difficult to maintain visibility and compete for healthcare procurement opportunities.Laboratories face difficulties securing specialized equipment and maintaining reliable diagnostic supply chains, which can delay installation and expansion of testing capacity. ECDC reported equipment shortages and procurement problems affecting public-health laboratories in its 2025 assessment. Long procurement timelines can postpone the deployment of new diagnostic platforms and reduce testing capacity. Delays in obtaining essential components can also disrupt manufacturers' delivery schedules and customer expansion plans.
June 2026 QIAGEN expanded its tuberculosis diagnostics portfolio by advancing molecular testing solutions for rapid detection of Mycobacterium tuberculosis and drug-resistant TB. The company focused on improving laboratory workflow efficiency and supporting decentralized testing across Europe.
May 2026 Roche Diagnostics expanded its infectious disease diagnostics portfolio by enhancing automated molecular testing platforms for tuberculosis detection and antimicrobial resistance analysis. The initiative focused on strengthening high-throughput laboratory capabilities across European healthcare systems.
April 2026 bioMérieux expanded its molecular diagnostics portfolio by advancing syndromic and PCR-based infectious disease testing solutions, including applications supporting rapid tuberculosis diagnosis and laboratory automation.
November 2025 Molbio Diagnostics expanded the availability of its Truenat™ molecular testing platform across Europe through new distribution partnerships, strengthening access to rapid point-of-care tuberculosis diagnostics and drug-resistance testing.